Translation of "Bcg vaccination" in German

The main use of BCG is for vaccination against tuberculosis.

Unlike the tuberculin skin test, the blood tests are not affected by the BCG vaccination.

In Europe, children are routinely given the BCG vaccination, which has greater than 80% effectiveness.

Nevertheless, the WHO still recommends BCG vaccination for children under one year of age in high risk countries.

The risk of disseminated BCG infection after BCG vaccination of infants up to 6 months of age who were exposed in utero to infliximab.

Biological tests for tuberculosis screening should be considered before starting Cimzia treatment if there is any potential latent tuberculosis infection, regardless of BCG vaccination.

Whereas the German Democratic Republic (GDR) sought to combat tuberculosis through statewide centralized preventive measures (BCG vaccination and serial x-ray screening), the Federal Republic of Germany achieved dramatic results with the early use of new tuberculosis antibiotics.

The tuberculin skin test, also known as PPD test, for detection of latent tuberculosis is only rarely used nowadays due to possible cross reactivity with nontuberculous mycobacteria (NTM) and previous BCG vaccination.

Compared to the existing vaccine M. bovis BCG, vaccination of mice with M. bovis BCG delta upk exhibited a lower bacterial load upon vaccination as well as an improved long-lasting protection against M. tuberculosis infection.

The BCG vaccine may give some protection, although its efficacy is questionable in adulthood.

For almost 100 years now, there has been one vaccine against tuberculosis, the so-called BCG vaccine.

In an age when medicine is making spectacular advances, we must acknowledge that the time has come for the traditional tuberculosis BCG vaccine to be replaced with a new, more modern and much more effective one.

A crucial point to emphasise is the fact that we do not have available clinical data to support the idea that one of the vaccine candidates under development could prove to be more effective than the vaccine currently in use, which is the Bacillus Calmette-Guérin (BCG) vaccine.

Administration of live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months following the mother's last adalimumab injection during pregnancy.

In infants exposed in utero to infliximab, fatal outcome due to disseminated Bacillus Calmette-Guérin (BCG) infection has been reported following administration of BCG vaccine after birth.

If you received Remicade while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 6 months after birth may result in infection with serious complications, including death.

Administration of live vaccines (e.g. BCG vaccine) to infants exposed to infliximab in utero is not recommended for at least 6 months after birth (see sections 4.4 and 4.5).

If you received Flixabi while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 6 months after birth may result in infection with serious complications, including death.

Administration of live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months following the mother's last adalimumab injection during pregnancy.

Indeed, the Bacille Calmette–Guérin (BCG) vaccine is almost 100 years old, while the most widely used diagnostic test, microscopic detection of bacilli in sputum, was developed 130 years ago.

The Bacille de Calmette et Guérin (BCG) vaccine – the only one available for the disease, and the main pillar of TB prevention – is only partly effective.

BCG vaccine) to infants exposed to infliximab in utero is not recommended for at least 6 months after birth (see sections 4.4 and 4.5).

If you received Inflectra while pregnant, administration of BCG vaccine (used to prevent tuberculosis) to your baby within 6 months after birth may result in infection with serious complications, including death.